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Introduction: Neutrophil gelatinase-associated lipocalin (NGAL) has been demonstrated to be a useful early
diagnostic biomarker of acute kidney injury (AKI) where the timing of the insult is certain. However, NGAL is not
well validated in adult critical care practice because of indeterminate timing of injury. Therefore, we sought to
establish the predictive ability of both urine and plasma NGAL to detect AKI in ICU patients.
Method: This prospective observational study was performed in a busy large district general hospital mixed
surgical-medical ICU in Reading, UK. Consecutive adult admissions to the ICU, with absence of chronic kidney
disease, renal transplant or AKI as defined by RIFLE criteria were included. Blood and urine specimens were
collected at admission and every 24 hours until 72 hours and tested for NGAL. The purpose of the study was
to assess whether urinary NGAL (uNGAL) or plasma NGAL (pNGAL) can predict the occurrence of AKI at an earlier
point of time than the conventional markers, that is creatinine and urine output as is used in RIFLE criteria.
Results: Over a 12-month period, 194 patients were enrolled. In total, 59 (30.4%) patients developed AKI. The
admission pNGAL and uNGAL were significantly higher in the patients who developed AKI compared to the
non-AKI patients (436 ng/mL (240, 797) versus 168 ng/mL (121.3, 274.3) P <0.001 and 342 ng/mL (61.5, 1,280) versus
34.5 ng/mL (11.5, 107.75) P <0.001 respectively). Hospital mortality was higher in the AKI group (17% versus 4%).
Plasma NGAL performed fairly on admission (AUROC 0.77) and thereafter performance improved at 24 and 48 hours
(AUROC 0.88 and 0.87) following ICU admission. Urine NGAL had a fair predictive value on admission (AUROC 0.79)
and at 24 hours (AUROC 0.78) and was good at 48 hours (AUROC 0.82).
Conclusions: In critically ill patients without pre-existing kidney disease, both pNGAL and uNGAL measured at
admission can predict AKI (defined by RIFLE criteria) occurrence up to 72 hours post-ICU admission and their
performance (AUROC) was fair. The accuracy of NGAL appeared to improve slightly as patients progressed through
their ICU stay. Serial measurements of NGAL (both pNGAL and uNGAL) may be of added value in an ICU setting to
predict the occurrence of AKI.Introduction
Acute kidney injury (AKI) is a complex and heterogeneous
process and is associated with high morbidity and mor-
tality especially among critically ill patients [1]. The main
pathophysiological process is renal tubular ischaemia,
which is often multifactorial including sepsis, major sur-
gery, low cardiac output, hypovolaemia and medication* Correspondence: r.matsa@yahoo.co.uk
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tient’s stay on the intensive care unit (ICU) [1,2].
Consensus diagnosis of AKI depends upon the detection
of oliguria and/or a rise of serum creatinine level [3].
However, changes in creatinine often lag behind reduc-
tions in the glomerular filtration rate (GFR) questioning
its utility as a biomarker to pre-empt deterioration in renal
function [4]. The Acute Dialysis Quality Initiative (ADQI)
consensus has recommended RIFLE criteria to stratify
three severity stages and two outcome stages for AKI -
risk, injury, failure, loss and end-stage renal failure; relying
on creatinine and urine output for their definition [3].td. This is an Open Access article distributed under the terms of the Creative
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AKI the morbidity and mortality, especially in ICU pa-
tients, has not changed for some years. One key factor
identified is a delay in diagnosis [5,6] suggesting a need for
more accurate and timely biomarkers. This would allow
earlier identification of patients who may benefit from
enhanced resuscitative care and pre-emptive renal support
to prevent further renal injury.
Neutrophil gelatinase-associated lipocalin (NGAL) has
been shown in multiple laboratory experiments to be
secreted early in the development of AKI. This has been
confirmed in several clinical settings including cardiac
surgery, following contrast administration, in the emer-
gency department and in paediatric intensive care [7-9].
To the best of our knowledge, only a few studies have
examined the role of NGAL to predict AKI occurrence
in a general adult ICU [10-15]. A recent systematic
review showed variability in the predictive ability of
NGAL [16] related to inconsistencies in study design,
patient inclusion and method of measurement. Most of
these studies have included patients on admission who
have pre-existing renal disease, (acute or chronic) lead-
ing to uncertainty about the timing and type of renal
insult. It is also unclear whether urinary NGAL (uNGAL)
or plasma NGAL (pNGAL) provide the best predictive
ability. This study was designed to examine the predictive
ability of both pNGAL and uNGAL in a heterogeneous
adult ICU population with no known pre-existing renal
disease prior to admission.
Materials and methods
Study design and setting
This prospective observational study was conducted in a
mixed medical and surgical adult ICU. All consecutive pa-
tients admitted from May 2011 until April 2012 were
screened. Patients were enrolled within their first 24 hours
of admission. The patient’s consent or the assent from
next of kin (if the patient was unable to consent) was ob-
tained by the trained staff prior to the participation in this
study. Only patients who offered their consent were
included in the study. If the patient lost their capacity
(having consented earlier), their original decision was up-
held. If a patient who was initially unable to consent (and
assent from the next of kin was obtained) decided to with-
draw from the study at a later stage, their wishes were
respected and they were excluded from the study. The
study was approved by the National Research Ethics Com-
mittee (Reference: Central London REC 3. 11/H0716/9)
and by the Department of Research and Development,
Royal Berkshire Hospital NHS Foundation Trust.
Inclusion and exclusion criteria
Consecutive adult (>18 years) patients admitted to the
ICU were screened for inclusion. Exclusion criteria wererefused consent, end-stage renal disease (ESRD), previ-
ous renal transplant, patients already on renal replace-
ment therapy (RRT), patients referred to the ICU for
RRT and patients with AKI as defined by RIFLE criteria
for risk, injury or failure.
Definition of acute kidney injury
We used the urine output and creatinine components of
the RIFLE criteria to define AKI [3]. The baseline creatin-
ine was the lowest value in the previous three months or,
when this was unknown, we estimated the GFR from the
modification of diet in renal disease (MDRD) formula and
back-calculated the creatinine [17]. The criteria were used
to exclude patients on admission with pre-existing renal
injury and were recorded daily in all patients for the first
72 hours of ICU stay and at discharge from the ICU.
Clinical and laboratory data collection
Data was collected daily on a case report form (CRF) for
each patient. Data on demographics, medical history and
admission diagnosis were collected in addition to daily
physiological variables, need for interventions such as
RRT and exposure to potential nephrotoxic compounds
(including contrast media and medications). Standard
laboratory blood tests were performed daily as part of
usual clinical care. Urine and blood samples for NGAL
were drawn on admission, at 24, 48 and 72 hours. The
reason for not collecting samples in such time periods
was discharge and/or death of the patients.
Sample processing and measurement for NGAL
The blood and urine samples were sent to our clinical bio-
chemistry laboratory and processed within 48 hours. The
blood samples were centrifuged at 3,200g for 10 minutes
and 2 mL aliquots of supernatant were stored at -70°C for
batch analysis. Urine samples were centrifuged at 4,000 g
for 5 minutes and 5 mL aliquots of supernatant were
stored at -70°C. The samples were assayed for NGAL
using Bioporto™ Diagnostics turbidimetric assay on
the Roche-Cobas c501 clinical chemistry analyser (Roche,
Basel, Switzerland). Laboratory investigators were blinded
to the clinical information throughout the study. In
order to validate the assay, the manufacturer’s per-
formance claims were compared with data collected
in the laboratory. The method was evaluated in accord-
ance with the Association of Clinical Biochemistry
document ‘Measurement verification in the clinical la-
boratory’ [18].
Statistical analysis
Means and standard deviations are used to describe
continuous variables. For heavily skewed distributions,
the median and interquartile range was used instead.
Categorical variables are expressed as proportions.
Figure 1 Flow chart of patient inclusion into the study.
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was used to explore the ability of NGAL to predict AKI
within 72 hours when measured on admission. ROC
curves are presented and the area under the curve
(AUC) has been calculated. Sensitivity and specificity,
positive and negative likelihood ratios, and positive and
negative predictive values are reported for a wide range
of thresholds, including the threshold that maximises
combined sensitivity and specificity (Youden’s index)
and the manufacturer recommended threshold (400 ng/ml
for plasma and 350 ng/ml for urine). The ability of NGAL
measured at 24 hours and 48 hours to predict subse-
quent AKI was explored to evaluate the benefit of ob-
taining serial NGAL measurements over time. Detailed
statistical methods are provided in Additional file 1.
Results
Patient demographics
The flow chart depicting the patient enrolment is de-
scribed in Figure 1. Five hundred and fifty consecutive
patients were screened between May 2011 and April
2012, with 194 enrolled in the study. We measured serial
pNGAL and uNGAL levels on admission and at every
24, 48 and 72 hours. However, the number of patients
for whom the NGAL was measured decreased with time
after admission to ICU as they were either discharged,
died and/or samples were not available (Table 1).
Fifty-nine patients (30.4%) developed AKI based on
RIFLE criteria and 42 patients (71.2%) developed AKI
within the first 24 hours of admission to the ICU. Of
these patients, 37% (n = 22) were medical and 63% (n = 37)
were surgical. The mean age group of the patients who de-
veloped AKI was higher than that of the non-AKI group
(62.2 ± 15.71 versus 59.18 ± 15.05). There was no signifi-
cant difference in the urine output between both the
groups (P = 0.098). The mean acute physiology and chronic
health evaluation II (APACHE II) scores among patients
with AKI were significantly higher than the group with no
AKI (16.69 ± 5.16 versus 12.8 ± 5.3). The AKI cohort was
more likely to have been exposed to nephrotoxic medi-
cations and radio-contrast dye (29% vs. 17%, P = 0.015).
Table 2 describes the patient characteristics.
The pNGAL and uNGAL concentrations both at the
time of ICU admission and at any given point of time
were significantly higher in AKI compared to that of the
non-AKI patients (Figures 2 and 3). The pNGAL gradually
increases with time whereas the uNGAL plateaus in
patients with AKI. Two patients among the group with
AKI required RRT. Mortality rate was higher among the
patients with AKI when compared to the patient group
with no AKI (17% vs. 4%, P = 0.001) although the overall
mortality was low (n = 15). Both pNGAL and uNGAL
levels were significantly higher in the patients who died
(pNGAL: 207 ng/mL (IQR 136 to 356) vs. 538 ng/mL(IQR 165 to 735) and uNGAL: 52.5 ng/mL (IQR 16 to
248) vs. 190 (IQR 21 to 2144) respectively) (Figure 4).
Plasma NGAL
The accuracy of pNGAL, measured on admission, to pre-
dict the occurrence of AKI within 72 hours was assessed.
The area under the ROC curve was 0.767 (Figure 5) and, at
the manufacturer recommended cut-point of 400 ng/mL,
had a sensitivity of 0.60 (95% confidence interval (CI):
0.43 to 0.74) (Table 1) and a specificity of 0.85 (95% CI:
0.77 to 0.91).
We measured serial NGAL measurements to deter-
mine utility in admitted patients. The pNGAL measured
at 24 hours to predict the occurrence of AKI at 48 and
72 hours of admission to ICU for a given threshold of
400 ng/mL had a sensitivity of 0.79 (95% CI 0.54 to 0.94)
and specificity of 0.75 (95% CI 0.64 to 0.85) and the per-
formance was good (area under the receiver operator
characteristic curve (AUROC) 0.88) (Figure 5). Similarly
the pNGAL measured at 48 hours to predict the occur-
rence of AKI at 72 hours performed fairly (sensitivity of











pNGAL at 0h for AKI occurrence at 24, 48 or 72 h 187 400 0.6 (0.43-0.74) 0.85 (0.77-0.91) 0.86 0.7668
pNGAL at 24h for AKI occurrence at 48 or 72 h 125 400 0.79 (0.54-0.94) 0.75 (0.64 -0.81) 0.93 0.8807
pNGAL at 48h for AKI occurrence at 72 h 77 400 0.73 (0.30-0.94) 0.95 (0.84-0.99) 0.92 0.8723
uNGAL at 0h hours for AKI occurrence at 24,
48 or 72 h
163 350 0.58 (0.39-0.75) 0.84 (0.76-0.90) 0.87 0.7914
uNGAL at 24h for AKI occurrence at 48 or 72 h 118 350 0.75 (0.48- 0.93) 0.82 (0.71-0.9) 0.94 0.7768
uNGAL at 48h for AKI occurrence at 48 or 72 h 68 350 0.75 (0.35-0.97) 0.88 (0.72- 0.97) 0.93 0.8220
NGAL, neutrophil gelatinase-associated lipocalin; AKI, acute kidney injury; CI, confidence interval; NPV, negative predictive value; AUROC, area under the receiver
operator characteristic curve; pNGAL, plasma neutrophil gelatinase-associated lipocalin; uNGAL, urine neutrophil gelatinase-associated lipocalin.
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0.69 to 0.93); AUROC 0.87) (Table 1).Urine NGAL
The predictive value of uNGAL (Table 1) measured at
admission, at a threshold of 350 ng/mL to predict the
occurrence of AKI within 72 hours of ICU admission
based on the serum creatinine values and urine output
measured at 24, 48 or 72 hours had a sensitivity of 0.58
(95% CI 0.39 to 0.75) and specificity of 0.84 (95% CI 0.76
to 0.90) and the performance was fair (AUROC 0.7914)
(Figure 5).
The uNGAL measured at 24 hours to predict the
occurrence of AKI at 48 and 72 hours of admission to
ICU had a sensitivity and specificity of 0.75 (95% CI 0.48
to 0.93) and 0.82 (0.71 to 0.90) respectively and the per-
formance was fair (AUROC 0.776). The uNGAL mea-
sured at 48 hours to predict the occurrence of AKI at 72
hours had a sensitivity of 0.75 (95% CI 0.35 to 0.97) and
specificity of 0.85 (95% CI 0.68 to 0.95) and the perform-
ance was good (AUROC 0.822) (Table 1).Discussion
Neutrophil gelatinase-associated lipocalin has been used
for the diagnosis, prognosis and severity assessment of
AKI and has been validated in paediatric populations
(where comorbidity is low) and in conditions where the
timing of the insult is clear (that is cardiac surgery and
so on) [20-24]. Its role in an adult ICU population has
not been well validated due to the heterogeneity and un-
certainty of the timing of the insult. The pathophysi-
ology and causes of AKI in the ICU could be indigenous
[25] and may differ from pre-ICU causes (low-volume
state, inotropes, contrast injury and so on). This has led
to problems in the design and interpretation of studies
in the general adult ICU patient cohort. In this study, we
sought to overcome these problems by excluding pa-
tients with pre-existing chronic kidney disease (CKD)
and/or AKI and by looking at the predictive value ofboth urinary and plasma NGAL at different time points
following admission.
We found the incidence of AKI was 30.4% (n = 59)
with 71% (n = 42) developing it within the first 24 hours.
This incidence correlated well with that anticipated from
our sample size calculation but was lower than that
found in previous studies due to the exclusion of those
patients with pre-existing renal disease [11,12,26]. Both
admission pNGAL and uNGAL were found to fairly
predict the occurrence of AKI at 72 hours following ICU
admission (AUROC 0.766 and 0.791 respectively). Our
study also showed that both pNGAL and uNGAL con-
centrations, at the time of ICU admission and at any
given point of time, were significantly higher in AKI com-
pared to that of the non-AKI patients (Figures 2 and 3).
de Geus et al. [10] found that the performance of pNGAL
at admission to predict the AKI severity to be similar to
our study [10]. However, utilising admission NGAL values
to predict AKI up to seven days can be associated with
certain confounding factors. Raised NGAL at admission
may correlate tubular ischemia at that point of time. The
possibility of a second or multiple insults after the initial
insult has been reversed is common in an ICU setting.
Therefore, prediction of AKI at a later point of time may
not represent true index performance. We have overcome
this issue by serial measurements of NGAL. Moreover the
study by de Geus included patients with previous renal
disease. This will affect the sensitivity and specificity of
the test. Another study [11] showed that performance of
pNGAL to predict AKI occurrence up to seven days was
excellent (AUROC 0.92). The small sample (n = 88) may
over-inflate the diagnostic accuracy. Cruz et al. [13] found
that the predictive value of admission pNGAL to diagnose
AKI up to 48 hours was fair (AUROC 0.78) but when
extended to five days, pNGAL performance was poor
(AUROC 0.67). This suggests that there is a wide variation
of NGAL assay performance when prediction is extended
beyond five days. Of note, a recent study [27] looking at
admission pNGAL to predict AKI occurrence up to 72
hours found results not dissimilar to our study (AUROC
Table 2 Demographic and case mix data for all patients
All patients No AKI AKI P value
Mean ± sd Mean ± sd Mean ± sd
Age (years) 60.1 ± 15.3 59.2 ± 15.1 62.2 ± 15.7 0.214
Female sex 86 (44%) 59 (44%) 27 (46%) 0.791
Weight (kg) 66.6 ± 11.0 66.8 ± 11.4 66.0 ± 10.2 0.619
Specialty code prior to unit admission (%)
Accident and Emergency 22 (11%) 13 (10%) 9 (15%) 0.05
Medicine 50 (26%) 38 (28%) 12 (20%)
Surgery 76 (39%) 46 (34%) 30 (51%)
Trauma 12 (6.2%) 11 (8%) 1 (2%)
Other 34 (17.5%) 27 (20.0%) 7 (11.9%)
ICU admission
APACHE II 14.0 ± 5.5 12.8 ± 5.3 16.7 ± 5.2 <0.001
Creatinine (mg/dL) 80.8 ± 29.1 68.2 ± 18.9 109.4 ± 28.0 <0.001
pNGAL on admission (ng/L) 209 (141, 389) 168.0 (121.3, 274.3) 436.0 (240.0, 797.0) <0.001
uNGAL on admission (ng/L) 53 (16, 283) 34.50 (11.5, 107.75) 342.00 (61.5, 1,280) <0.001
Urine output (mL/hour) 67 (40, 100) 70 (45, 100) 60 (36, 90) 0.098
MAP (mmHg) 78.6 ± 16.7 80.54 ± 16.78 74.12 ± 15.82 0.012
Mechanical ventilation (%) 84 (43%) 58 (43%) 26 (44%) 0.886
Vasopressors (%) 54 (28%) 29 (21%) 25 (42%) 0.003
Sepsis (%) 15 (8%) 7 (5%) 8 (14%) 0.136
RRT in first 24 hours (%) 2 (1%) 0 (0%) 2 (3%) 0.093
Nephrotoxic agents (%) -
Radio contrast dye 36 (19%) 19 (14%) 17 (29%)
ACE inhibitor 55 (28%) 37 (27%) 18 (31%)
Diuretics 37 (19%) 22 (16%) 15 (25%)
ARBs 10 (5%) 5 (4%) 5 (8%)
NSAIDs 9 (5%) 7 (5%) 2 (3%)
Cyclosporin 1 (1%) 0 1 (2%)
None 104 (54%) 76 (56%) 28 (47%)
Outcome
Hospital mortality (%) 15 (8%) 5 (4%) 10 (17%) 0.001
AKI, acute kidney injury; sd, standard deviation; ICU, intensive care unit; APACHE II, acute physiology and chronic health evaluation II; pNGAL, plasma neutrophil
gelatinase-associated lipocalin; uNGAL, urine neutrophil gelatinase-associated lipocalin; MAP, mean arterial pressure; RRT, renal replacement therapy; ACE inhibitor,
angiotensin-converting enzyme inhibitor; ARBs, angiotensin II receptor blockers; NSAIDs, non-steroidal anti-inflammatory drugs.
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kidney disease we have determined the diagnostic accuracy
more precisely.
Many of the preliminary studies performed to evaluate
the diagnostic value of NGAL were done using urine
analysis yielding promising results, however, these studies
were done in a paediatric, non-ICU population, and where
time of injury was clearly defined [9,20-23]. Siew et al.
[15] found that the admission uNGAL values to predict
AKI at 24 hours among ICU patients was fair (AUROC
0.71) but did not perform well when extended to 48 hours
(AUROC 0.64). The study used a convenience samplefrom a large biomarker study in acute lung injury and also
included patients with previous and existing kidney injury.
Another study performed by Makris et al. [28] showed
that the uNGAL performance to predict AKI up to five
days was excellent (AUROC 0.97). The study mostly
included trauma patients. The generalisability of this
study, however, is limited due to the small sample size
(n = 31). Other ICU studies investigating uNGAL to pre-
dict AKI occurrence up to five days or more have shown
variable results [10,11,26]. Under normal circumstances,
the filtered NGAL is completely absorbed by the proximal
convoluted tubule (PCT) and therefore there should be
Figure 2 Serial mean plasma NGAL measurements in those with and without AKI. AKI, acute kidney injury; NGAL, neutrophil gelatinase-
associated lipocalin.
Figure 3 Serial mean urine NGAL measurements in those with and without AKI. AKI, acute kidney injury; NGAL, neutrophil gelatinase-
associated lipocalin.
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Figure 4 Plasma and urine NGAL measurements in patients who are alive and dead. NGAL, neutrophil gelatinase-associated lipocalin.
Figure 5 AUROC curves demonstrating the predictive ability of plasma and urine NGAL and urine NGAL at 0, 24 and 48 hours to predict AKI
up to 72 hours. AKI, acute kidney injury; AUROC, area under the receiver operator characteristic curve; NGAL, neutrophil gelatinase-associated lipocalin.
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to the PCT, NGAL is not absorbed and accounts for the
rise in NGAL levels in urine. Further evidence suggests
that the NGAL production can arise from the injured
distal nephron [8]. This could explain the persistent rise in
uNGAL in patients with ongoing injury. When the GFR is
reduced, serum creatinine increases. Similarly, systemic
NGAL (pNGAL) levels increase as NGAL filtration is
decreased.
Our study has looked at the occurrence of AKI up to
72 hours. By taking serial samples we were able to show
that both uNGAL and pNGAL continue to have fair to
good predictive ability (Table 1) in admitted patients
suggesting there may be a role in the daily detection of
renal injury. The 72-hour time frame is a reasonable
time for the pNGAL to accumulate. Of note, the kinetics
of pNGAL and uNGAL in our study suggest pNGAL
gradually increases with time whereas the uNGAL
reaches a plateau (Figures 2 and 3). However, this find-
ing is clearly limited by the small number of samples at
48 hours.
A small study in a selected group of patients with
septic shock [12] showed that uNGAL performed better
(AUC 0.86) than the pNGAL (0.67) to predict the AKI
occurrence 12 hours ahead of time. Therefore, pNGAL
may not be a good predictor if the prediction time is
short as it may take some time to accumulate and
uNGAL may be a better marker in triage situations.
Therefore, uNGAL could be a better predictor in condi-
tions where AKI is anticipated that is radio-contrast-
induced AKI, coronary artery bypass graft (CABG) and
so on. However, one drawback is that sometimes in
critically unwell patients, obtaining urine may be difficult
and sometimes uNGAL may be elevated with urinary tract
infection [14].
The threshold values we used were high compared to
similar studies. The difference may be secondary to the
type of assays and platform used. We chose an immuno-
turbidimetric assay due to the fast assay time (10 minutes),
a platform compatible with most analysers available in UK
laboratories [30,31] and a wide measuring range (25 to
5000 ng/mL) that will allow easy validation in clinical
practice.
Our study makes an important contribution to the
current body of literature on NGAL and AKI. To the
best of our knowledge, this is the first study to prospect-
ively evaluate both plasma and urine NGAL in adult ICU
patients where pre-existing renal disease has been ex-
cluded. Our study has certain important strengths. First,
this is the first published UK study on NGAL to predict
AKI in ICU patients; second, our strict exclusion criterion
excluded pre-existing kidney disease; third, we powered
our study to ensure statistical robustness; fourth, we
demonstrated the value of serial sampling of pNGAL anduNGAL; finally, we used a standardised user-friendly
platform, reducing laboratory measurement error and
allowing other investigators to validate our findings.
Our study also has deficiencies. This is a single-centre
study and hence care should be exercised when general-
ising the results. Although we excluded patients with
AKI prior to admission, there may be a small number of
patients who might have had an undetected renal insult
in the few hours prior to ICU admission. This is an im-
portant limitation in any study of early biomarkers in an
unselected ICU population. Second, we did not perform
a sensitivity analysis to discount comorbidities that could
account for the changes in NGAL. Third, there had been
a decrease in the number of patients for whom the serial
NGAL levels were measured with time (that is 0, 24 and
48 hours). In a general ICU setting this attrition is
unavoidable. In some cases, the samples were not avail-
able from the patients due to anuresis and/or in the
process of end-of-life care. Fourth, urine NGAL levels
were not corrected for urinary creatinine concentration
to account for possible dilution of urine. Finally, we were
unable to correlate NGAL values with clinical outcomes
such as mortality and need for RRT due to the small
numbers in these groups.
Conclusions
Our study showed that both pNGAL and uNGAL levels
measured at admission to ICU can predict an occurrence
of AKI for up to 72 hours of ICU stay. The performance
as determined by AUROC is fair. This performance was
sustained when measured at serial time points throughout
the ICU stay.
Key messages
 In patients with no kidney disease prior to
admission to ICU, both pNGAL and uNGAL have a
fair predictive value to diagnose the occurrence of
AKI for up to 72 hours.
 This performance is sustained when measured at
serial time points throughout the ICU stay.
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